[Imatinib for gastro-intestinal stromal tumors]
Department of Science and Technology - Brazilian Health Technology Assessment General Coordination
Record ID 32006001464
Evaluate the effectiveness and safety of imatinib for gastrointestinal stromal tumors.
Authors' recomendations: While new studies are not undertaken, possible benefits and harms of imatinib should be systematically monitored in all patients taking such biological therapy for gastrointestinal stromal tumor in Brazil. Clinical trials have been carried out (NCT00103168; NCT00041197; NCT00116935). They are evaluating the neoadjuvant and adjuvant approaches, period oftreatment (12 month versus 36 month) and imatinib associated with other chemotherapy regimens.
Project Status: Completed
URL for project: http://portal.saude.gov.br/portal/arquivos/pdf/imatinib_for_gastrointestinal_stromal_tumors.pdf
Year Published: 2005
URL for published report: http://portal2.saude.gov.br/rebrats/visao/estudo/detEstudo.cfm?codigo=108&evento=6&v=true
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Antineoplastic Agents
- Gastrointestinal Neoplasms
Organisation Name: Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
Contact Address: Ministerio da Saude, Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia, Esplanada dos Ministerios, Edificio sede; bl "G" - 8 andar - SL 834, CEP: 70058-900, Brasilia, DF Brazil, Tel: +55 61 3315 3197 Fax: +55 61 3315 3850
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Department of Science and Technology - Brazilian Health Technology Assessment General Coordination (DECIT-CGATS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.